These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12091773)

  • 1. Pharmacologic therapy of lipid disorders in the elderly.
    Aronow WS
    Am J Geriatr Cardiol; 2002; 11(4):247-56. PubMed ID: 12091773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of new atherothrombotic brain infarction in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol >or=125 mg/dl treated with statins versus no lipid-lowering drug.
    Aronow WS; Ahn C; Gutstein H
    J Gerontol A Biol Sci Med Sci; 2002 May; 57(5):M333-5. PubMed ID: 11983729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of older persons with hypercholesterolemia with and without cardiovascular disease.
    Aronow WS
    J Gerontol A Biol Sci Med Sci; 2001 Mar; 56(3):M138-45. PubMed ID: 11253155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesterol 2001. Rationale for lipid-lowering in older patients with or without CAD.
    Aronow WS
    Geriatrics; 2001 Sep; 56(9):22-5, 28-30. PubMed ID: 11582971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholesterol and atherosclerosis: a contemporary perspective.
    Kashyap ML
    Ann Acad Med Singap; 1997 Jul; 26(4):517-23. PubMed ID: 9395824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER).
    Kawada-Watanabe E; Ogawa H; Koyanagi R; Arashi H; Yamaguchi J; Matsui K; Hagiwara N
    J Cardiol; 2017 Mar; 69(3):536-541. PubMed ID: 27349705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of hyperlipidemia with statins in the older patient.
    Aronow WS
    Clin Interv Aging; 2006; 1(4):433-8. PubMed ID: 18046920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk.
    Jacobson TA
    Mayo Clin Proc; 2011 Aug; 86(8):762-80. PubMed ID: 21803958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum.
    Ascaso JF; Fernández-Cruz A; González Santos P; Hernández Mijares A; Mangas Rojas A; Millán J; Felipe Pallardo L; Pedro-Botet J; Pérez-Jiménez F; Pía G; Pintó X; Plaza I; Rubiés-Prat J;
    Am J Cardiovasc Drugs; 2004; 4(5):299-314. PubMed ID: 15449972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia.
    McLaughlin T; Abbasi F; Lamendola C; Leary E; Reaven GM
    Metabolism; 2002 Oct; 51(10):1355-9. PubMed ID: 12370858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
    Ahmed MH
    J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetic dyslipidemia.
    Kreisberg RA
    Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemfibrozil in Combination with Statins-Is It Really Contraindicated?
    Wiggins BS; Saseen JJ; Morris PB
    Curr Atheroscler Rep; 2016 Apr; 18(4):18. PubMed ID: 26932225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.